Browse the evidence

Lifestyle interventions, particularly those involving Mediterranean diets enriched with polyphenols, can reduce DNA methylation age (epigenetic aging) in overweight and obese individuals.

Healthy lifestyle choices, including diet and exercise, can slow down your biological aging process. This means you can potentially age slower than your chronological age suggests by maintaining a healthy weight and diet.

Deprescribing GLP-1 agonists in patients with Type 2 Diabetes does not result in weight regain or loss of glycemic control if the patient maintains Carbohydrate Restricted Nutrition Therapy (CRNT) supported by continuous remote care.

If you are taking a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes, you may be able to stop the medication without regaining weight or losing blood sugar control, provided you switch to a strict low-carbohydrate diet (under 30g carbs/day) and maintain nutritional ketosis. This approach mimics the drug's hormonal effects on hunger and satiety. You should work with a healthcare provider to monitor your progress and determine if you are a candidate for deprescription.

Carbohydrate Restricted Nutrition Therapy (CRNT) induces hormonal changes (lower ghrelin, higher GLP-1/CCK) that reduce hunger and appetite, thereby supporting weight maintenance after GLP-1 deprescription.

The reason low-carb diets help you stay full is not just willpower; they biologically alter your hunger hormones. Ketosis lowers ghrelin (the hunger hormone) and increases satiety hormones, making it easier to maintain weight loss without constant hunger.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GLP-1/GIP agonists (tirzepatide) are the most promising pharmacological treatments for obesity in older adults, offering favorable efficacy and safety profiles, though specific guidelines are currently lacking.

For older adults with obesity, GLP-1 agonists like liraglutide and semaglutide are currently the most effective pharmacological options. They work by mimicking hormones that regulate appetite and blood sugar. While they cause significant weight loss, there is a risk of muscle loss, so these medications should ideally be used alongside resistance exercise and adequate protein intake. Start with a low dose and increase slowly to manage stomach side effects. Note that data for those over 75 is limited.

Oral semaglutide administration in patients with type 2 diabetes significantly reduces body weight, HbA1c, and total cholesterol within 3-6 months, with additional systolic blood pressure reduction observed by 6-12 months.

If you have Type 2 Diabetes, oral semaglutide can significantly improve your weight, blood sugar (HbA1c), and cholesterol levels within the first 6 months, with blood pressure improvements continuing up to a year. While gastrointestinal side effects like nausea are common and may lead some to stop the medication, serious safety issues were not observed in this real-world study. It serves as a viable alternative to injectable GLP-1s, particularly for those who prefer oral medication or have needle phobia.

Athletes and active individuals prioritize 'enhanced muscular recovery' as the primary claim for sports nutrition products, with 25% ranking it first and 73% in their top three priorities.

If you are an athlete looking for sports nutrition products, prioritize those that explicitly support muscle recovery. Look for whole-food-based options rather than just supplements, as this is the most desired feature for this group. Ensure the product has scientific backing, as 87% of users rate scientific proof as important.

Athletes and active individuals prefer whole food nutritional products over supplements, powders, or bars for both performance and recovery.

When choosing sports nutrition products, look for whole food options rather than isolated supplements or powders. This format is preferred by athletes for both performance and recovery. Ensure the product is scientifically proven, as this is a key factor for 87% of users.

Nutritional profile is the most important attribute for purchasing sports nutrition products, followed by taste and accessibility.

When selecting sports nutrition products, prioritize those with a clear and beneficial nutritional profile. Taste and accessibility are also important secondary factors. Ensure the product has scientific proof, as this is highly valued.

GLP-1 receptor agonists may improve psoriasis symptoms (PASI score) in patients with Type 2 Diabetes, though evidence from randomized controlled trials is mixed.

If you have psoriasis and Type 2 Diabetes, GLP-1 medications might help improve your skin symptoms, but this is not guaranteed. The most reliable benefit is the protection against heart disease and stroke. Discuss with your doctor if the potential skin benefits, combined with cardiovascular protection, outweigh the need for an injection.

Once-weekly subcutaneous administration of the glucagon/GLP-1 receptor co-agonist NNC9204-1177 produces dose-dependent, clinically significant body weight loss in adults with overweight or obesity, but is associated with unacceptable safety concerns including increased heart rate, hepatic disturbances, and impaired glucose tolerance.

This specific drug (NNC9204-1177) is not available for clinical use because it caused unacceptable side effects like increased heart rate and liver issues, despite causing significant weight loss. However, it highlights that combining GLP-1 and glucagon pathways can lead to substantial weight loss, which is why other approved GLP-1 medications exist. If you are considering GLP-1 therapy, discuss the specific safety profile of the approved options with your healthcare provider.

Oral semaglutide (up to 7 mg/day) produces significant weight loss (mean 4.5 kg) and BMI reduction in psychiatric patients with antipsychotic-induced weight gain over 16 weeks, with a safety profile comparable to metformin.

For psychiatric patients struggling with weight gain from antipsychotics, oral semaglutide is a viable treatment option. Start with 3 mg daily for the first month, then increase to 7 mg daily if tolerated. Expect about 4.5 kg (10 lbs) of weight loss over 4 months. Side effects like nausea are common but usually mild and go away. This treatment does not worsen psychiatric symptoms and may even improve quality of life.

Combined blockade of GDF8 (myostatin) and Activin A using monoclonal antibodies significantly increases lean muscle mass and decreases fat mass in postmenopausal women, with effects reversing to baseline upon cessation of treatment.

For postmenopausal women seeking to increase muscle mass, blocking both myostatin and activin A via antibody therapy produces significant muscle growth and fat loss. However, this effect is not permanent; stopping treatment leads to a return to baseline muscle size within about 6 months. The treatment requires regular IV infusions and carries mild side effects like muscle spasms. It is not a lifestyle intervention but a medical therapy requiring clinical supervision.

In carriers of the BDNF rs10835211 GG genotype, high carbohydrate intake (>48% of energy) is associated with lower fat-free mass and skeletal muscle mass compared to lower intake, whereas high fiber intake (>18g/day) is associated with higher fat-free mass but also higher total cholesterol and LDL-C.

If you carry the BDNF rs10835211 GG genotype, your body composition response to macronutrients differs from the general population. High carbohydrate intake (>48% of calories) may be associated with lower muscle mass in this group. However, ensuring adequate fiber intake (>18g/day) may support higher fat-free mass, though it was also linked to higher cholesterol in this specific study. Focus on fiber-rich carbohydrate sources and monitor lipid profiles.

In BDNF rs10835211 GG genotype carriers, high protein intake (>18% of energy) is associated with higher waist circumference, BMI, body fat, and insulin resistance (HOMA-IR), while high fat intake (>30% of energy) is associated with higher visceral adipose tissue (VAT) and HDL-C.

If you carry the BDNF rs10835211 GG genotype, be cautious with high-protein (>18% energy) and high-fat (>30% energy) diets. This study links these intake levels in this group to higher waist circumference, visceral fat, and insulin resistance. Consider balancing these macros and monitoring waist circumference and fasting insulin.

In BDNF rs10835211 GG genotype carriers, higher daily energy intake (>1800 kcal) is associated with lower fasting insulin, lower HbA1c, and lower HOMA-IR compared to lower energy intake, despite similar or higher body weight.

If you carry the BDNF rs10835211 GG genotype, restricting calories too severely (<1800 kcal) might be associated with higher insulin resistance and HbA1c. Ensure you are eating enough to support your metabolic health, as this group may respond differently to caloric restriction.

Female resistance-trained athletes tend to spare more lean mass than males during caloric restriction, potentially due to differences in training experience, pre-diet volume, and energy deficit.

Female athletes may naturally preserve muscle better during a cut than males, but they should still prioritize high training volume to maximize this benefit.

Intensive Weight Management Programmes (IWMPs) utilizing Total Diet Replacement (TDR) achieve substantial, sustained weight loss (5-15%) and metabolic improvements in populations with obesity and type 2 diabetes, though specific evidence for women with PCOS is currently insufficient.

For women with PCOS, standard diet and exercise advice often fails to produce lasting metabolic benefits. Intensive programs using meal replacements (TDR) for a few months, followed by a structured return to food, can produce significant weight loss (5-15%) and improve metabolic health. However, because specific studies on PCOS are lacking, this approach should be considered promising but unproven for this specific group, requiring careful monitoring.

Quercetin supplementation at 1000 mg/day for >7 days accelerates recovery of muscle function and reduces muscle soreness and oxidative stress after intense exercise.

If you engage in intense exercise that causes muscle damage, taking 1000 mg of quercetin daily for at least 7 days (up to 12 weeks) may help reduce muscle soreness and speed up recovery. This is generally considered safe for young adults.

Higher frequency, power-focused intensity, and traditional strength training programs yield superior improvements in walking capacity, speed, and quality of life compared to other prescriptions.

To get the most out of strength training after a stroke, focus on moving quickly (power) rather than just lifting heavy weights. Aim for more frequent sessions and traditional exercises that target specific muscle groups. This approach has been shown to significantly improve walking speed and quality of life.

Adherence to a ketogenic-like diet (KLD) results in a transient increase in LDL cholesterol but a sustained improvement in the triglyceride-to-HDL ratio (log(TG/HDL)), indicating a shift toward a less atherogenic LDL profile compared to ultra low-fat diets (ULF).

If you follow a very low-carb diet and see your LDL cholesterol rise, do not automatically assume your heart risk has increased. Look at your Triglyceride-to-HDL ratio; if it has improved significantly, it suggests your LDL particles have become larger and less harmful, which is a positive metabolic shift. Maintain your diet quality by minimizing added sugars and refined grains.

Both ketogenic-like (KLD) and ultra low-fat (ULF) diets produce similar weight loss and improvements in insulin resistance when adhered to, regardless of macronutrient composition.

You can lose significant weight and improve insulin resistance on either a very low-carb or a very low-fat diet, provided you stick to it. The specific macronutrient ratio matters less than your ability to maintain the diet and create a caloric deficit. Choose the pattern that allows you to minimize added sugars and refined grains while maximizing vegetables.

Tirzepatide demonstrates superior efficacy compared to Semaglutide in reducing HbA1c levels, but shows no clear superiority in weight loss or FBS reduction.

If your current Semaglutide treatment is not lowering your HbA1c enough, switching to Tirzepatide may provide better blood sugar control. However, do not expect significantly more weight loss from this switch, as both drugs appear to offer similar weight reduction benefits in this analysis.

Switching from Liraglutide to Semaglutide results in significant additional weight loss and FBS reduction, but does not significantly impact HbA1c levels.

If you are currently on Liraglutide and struggling with weight or fasting blood sugar, switching to Semaglutide may help you lose more weight and lower your FBS. However, this switch is unlikely to significantly improve your HbA1c levels.

Moderate consumption of dairy products, particularly fermented dairy like yogurt, is associated with reduced cardiovascular risk and lower long-term weight gain, contrary to historical concerns about saturated fat.

You can include moderate amounts of dairy in your diet, especially fermented options like yogurt and cheese. They are linked to lower cardiovascular risk and weight gain. Avoid very high intake (>1000g/day).